An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe pediatric genetic disease.
This article takes an in-depth look at how lipid-based drug delivery systems can be used as a bioavailability enhancing technology, as well as the softgel dosage form for their delivery.
Flu vaccine production – tracking and optimizing yield throughout the development and manufacturing process.
A small sized pharmaceutical company was approaching the final phases of a large phase III global multiple treatment arm oncology study that involved comparator drug. The study criteria required the client to provide study medication to patients active at the conclusion of the study until the drug would be commercially available, when it could then be prescribed to patients continuing treatment.
A Q&A session with formulation and bioavailability experts on addressing formulation challenges for pediatric populations.
According to over 200 life sciences companies surveyed, the number one challenge in speeding products from R&D to patients is quality management, which may surprise many executives that have spent the past decade focused on other issues like validation, regulatory, or supply chain.
Insights on how patient-centric options are extending to clinical trial design, with sponsors considering how clinical trial materials can be formulated, packaged, and delivered in a manner that is efficacious.
Current market conditions such as regulations and mergers or acquisitions make improving compliance and manufacturing efficiency while driving to grow revenue and margins difficult.
Biocom, the association representing the life science industry of California, concluded its Regenerative Medicine Advocacy Fly-In to Washington, D.C. yesterday, the culmination of almost a year of efforts to elevate the voice of California’s regenerative medicine community